Shareholders that lost money on Skye Bioscience, Inc. (SKYE) should contact The Gross Law Firm about pending Class Action - SKYE

Core Viewpoint - Skye Bioscience, Inc. is facing a class action lawsuit due to allegations of misleading statements regarding its lead product candidate, nimacimab, which was claimed to be less effective than previously communicated [3][4]. Group 1: Allegations and Class Period - The class period for the lawsuit is from November 4, 2024, to October 3, 2025 [3]. - Allegations include that the company overstated the clinical, regulatory, and commercial prospects of nimacimab, leading to materially false and misleading public statements [3]. Group 2: Shareholder Actions - Shareholders who purchased SKYE shares during the class period are encouraged to register for the class action, with a deadline of January 16, 2026, to seek lead plaintiff status [4]. - Once registered, shareholders will receive updates through a portfolio monitoring software regarding the case's progress [4]. Group 3: Law Firm's Role - The Gross Law Firm is representing the shareholders and is recognized for its commitment to protecting investors' rights against deceit and fraud [5]. - The firm aims to recover losses incurred by investors due to the alleged misleading statements by Skye Bioscience [5].